Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Assets: 2012-2025

Historic Assets for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $280.7 million.

  • Enanta Pharmaceuticals' Assets fell 25.47% to $280.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $280.7 million, marking a year-over-year decrease of 25.47%. This contributed to the annual value of $280.7 million for FY2025, which is 25.47% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Assets of $280.7 million as of Q3 2025, which was down 6.74% from $301.0 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Assets registered a high of $495.2 million during Q2 2023, and its lowest value of $280.7 million during Q3 2025.
  • Its 3-year average for Assets is $377.7 million, with a median of $376.7 million in 2024.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Assets grew by 28.54% in 2023, and later dropped by 25.47% in 2025.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Assets stood at $440.6 million in 2021, then fell by 21.12% to $347.5 million in 2022, then increased by 23.30% to $428.5 million in 2023, then fell by 18.64% to $348.6 million in 2024, then fell by 25.47% to $280.7 million in 2025.
  • Its last three reported values are $280.7 million in Q3 2025, $301.0 million for Q2 2025, and $323.0 million during Q1 2025.